This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Eviö, S. Articles by Välimäki, M. J. Search for Related Content PubMed PubMed Citation Articles by Eviö, S. Articles by Välimäki, M. J.

Effects of Alendronate and Hormone Replacement Therapy, Alone and in Combination, on Bone Mass and Markers of Bone Turnover in Elderly Women with Osteoporosis

Department of Obstetrics and Gynecology (S.E., A.T., K.L., O.Y.) and Division of Endocrinology (M.J.V.), Department of Medicine, Helsinki University Central Hospital, FIN-00029 HUS Helsinki, Finland

Address all correspondence and requests for reprints to: Dr. Matti Välimäki, Division of Endocrinology, Department of Medicine, Helsinki University Central Hospital, P.O. Box 340, FIN-00029 HUS Helsinki, Finland. E-mail: matti.valimaki{at}hus.fi.

The aim of the study was to compare alendronate, hormone replacement therapy (HRT), and their combination in treatment of osteoporosis in elderly postmenopausal women. Ninety patients, aged 65–80 yr (mean 71), with a T-score of bone mineral density (BMD) of 2.5 or less at either the lumbar spine or the femoral neck were randomized to receive daily 10 mg alendronate (n = 30), 2 mg estradiol plus 1 mg norethisterone acetate (n = 30) (HRT), or their combination (n = 30) for 2 yr. BMD of the lumbar spine and the upper femur was measured at baseline and after 1 and 2 yr of treatment. Urinary excretion of type I collagen aminoterminal telopeptide as related to creatinine and serum type I procollagen aminoterminal propeptide was assayed at baseline and at 6-month intervals thereafter. Increases of 9.1–11.2% in lumbar spine BMD at 2 yr were similar in the study groups. Only HRT increased femoral neck BMD statistically significantly (P < 0.0001 for a change from baseline) at both 1 (+4.9%; P =NS vs. the other groups) and 2 yr (+5.8%; P < 0.05 vs. the other groups). Total hip BMD increased similarly in all study groups. Percentage reductions in urinary type I collagen aminoterminal telopeptide in the HRT group (60.2–62.7%) were significantly smaller than those in the combination group (78.1–80.4%) (P < 0.0001–0.0069) and the alendronate-only group (72.4–76.1%) (P = 0.047 at 24 months). Serum type I procollagen aminoterminal propeptide decreased less in the HRT group (53.6–59.8%) than in the other groups [73.0–75.0% in the alendronate group (P < 0.001 at 12 months); 67.0–71.5% in the combination group (P < 0.0001 at 12 months, P = 0.013 at 24 months)]. We conclude that in elderly postmenopausal women with osteoporosis, the combination of HRT and alendronate did not offer an extra gain of bone mass over either treatment alone. In terms of BMD changes, the single treatments were equally effective, but the reductions in bone markers were less with HRT than with alendronate.

This work was supported by Research Funding from Helsinki University Central Hospital (Erityisvaltionosuus) and grants from Biomedicum Helsinki Foundation; Paulo Foundation; Emil Aaltonen Foundation; Finnish Menopause Society; La Carita Foundation, Finland; and Merck, Inc.

Abbreviations: BMD, Bone mineral density; CV, coefficient of variation; HRT, hormone replacement therapy; NTX, N-telopeptide; PINP, aminoterminal propeptide of human type I procollagen; S-25(OH)D, serum 25-hydroxyvitamin D.

This article has been cited by other articles:

				G. PAN, Z. YANG, S. W. BALLINGER, and J. M. MCDONALD Pathogenesis of Osteopenia/Osteoporosis Induced by Highly Active Anti-Retroviral Therapy for AIDS Ann. N.Y. Acad. Sci., April 1, 2006; 1068(1): 297 - 308. [Abstract] [Full Text] [PDF]

				S. L. Greenspan, N. M. Resnick, and R. A. Parker Early Changes in Biochemical Markers of Bone Turnover Are Associated with Long-Term Changes in Bone Mineral Density in Elderly Women on Alendronate, Hormone Replacement Therapy, or Combination Therapy: A Three-Year, Double-Blind, Placebo-Controlled, Randomized Clinical Trial J. Clin. Endocrinol. Metab., May 1, 2005; 90(5): 2762 - 2767. [Abstract] [Full Text] [PDF]

				P. M. Crofton, N. Evans, M. R.H. Taylor, and C. V. Holland Procollagen Type I Amino-Terminal Propeptide: Pediatric Reference Data and Relationship with Procollagen Type I Carboxyl-Terminal Propeptide Clin. Chem., November 1, 2004; 50(11): 2173 - 2176. [Full Text] [PDF]

				Osteoporosis Obstet. Gynecol., October 1, 2004; 104(4_suppl): 66S - 76S. [Full Text] [PDF]